Ads
related to: b cell- Dosing Information
Review Dosing & Administration
Options For Your Patients.
- Resources For Physicians
Review Billing, Enrollment, Patient
Tools & More Physician Resources.
- Patient Profiles
This Treatment Option May Be Right
For Your Severe Asthma Patients.
- Stay Up To Date
Sign Up To Receive Severe Asthma
Info, News & Updates.
- Clinical Trial Design
Review Info On A Robust Clinical
Trial Program. Learn More.
- Clinical Information
Learn How Reductions In
Exacerbations May Be Possible.
- Dosing Information
Search results
...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...
Morningstar· 4 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma ...
...BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE...
Morningstar· 5 days agoFood and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative ...
Rituximab Tied to Increased Infection Risk in RRMS
Medscape· 7 days agoThe B-cell–depleting treatment rituximab was associated with a twofold increased risk for infection in RRMS, regardless of treatment duration or whether the patient had received other DMTs first.
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for...
Sjogren's Syndrome
Health· 5 hours agoRelated Conditions Due to inflammation and immune changes in Sjogren’s, about 5% of people with Sjogren’s syndrome eventually develop a type of blood...
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
Morningstar· 5 days agoThe biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-< ...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 6 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Zacks via Yahoo Finance· 8 hours agoNurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 4.4% on Analyst Upgrade
ETF DAILY NEWS· 14 hours agoNurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) shares were up 4.4% on Tuesday after HC Wainwright raised their price target on the stock from $19.00 to $26.00. HC Wainwright currently ...
Ad
related to: b cell
